Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of HRTIS.HE is 2.00 and suggests 73.9% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to